ClinicalTrials.gg
CompletedNCT04608955WX-081Updated Sep 11, 2023

Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081

A Phase 2 interventional study of WX-081 and Bedaquiline in Pulmonary Tuberculosis, sponsored by Shanghai Jiatan Pharmatech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-11.

Sponsored by Shanghai Jiatan Pharmatech Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies in Tuberculosis, Pulmonary with a site in China — 12 open to participants now, 14 under way, 6 of them phase 3. Tuberculosis, Pulmonary · China.

Enrollment
19th of 21
99 · median 280
Started
2020
with 1 other
Phase 2
4 of 28
1 open now
Registered
12th of 28
by date
Lead sponsor
2 of 28
Shanghai Jiatan Pharmatech Co., Ltd

Among the 28 studies in Tuberculosis, Pulmonary with a site in China, this one is the 19th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 12th registered.

Tuberculosis, Pulmonary

319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

12 of the 28 studies in Tuberculosis, Pulmonary with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Tuberculosis, Pulmonary with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, parallel, open-label, positive-controlled Phase 2 clinical trial, which aims to evaluate the early bactericidal activity, safety and tolerability of WX-081 in patients with drug-naive\&susceptible and drug-resistant tuberculosis. Also the efficacy of WX-081 will be explored in participants with drug-resistant tuberculosis.

Read the detailed description

This is a Phase 2, multi-center, randomized, parallel, open-label, positive-controlled clinical trial. The objective of this trial is to evaluate the early bactericidal activity, safety and tolerability of WX-081 patients with drug-naive\&susceptible and drug-resistant tuberculosis. and the efficacy in participants with drug-resistant tuberculosis.

This trial will be divided into core research stage (stage 1) and extended research stage (stage 2). During stage 1, a panel of 59 participants with drug-naive\&susceptible tuberculosis will be randomized to receive either WX-081(including 3 groups:150mg qd, 300mg qd, 450mg qd. n=12 per group) or standard treatment (n=8) for 2 weeks, and then followed by a follow-up period of 2 weeks. A panel of 40 participants with drug-resistant tuberculosis will be randomized to receive either WX-081 (400mg qd, n=20) or bedaquiline (400mg qd, n=20) for 2 weeks. During stage 2, the 40 participants with drug-resistant tuberculosis will receive WX-081(150mg qd) + MBT treatment (ie. multi-drug background treatment) and bedaquiline (200mg tiw) +MBT treatment for 6 weeks respectively, and then followed by a follow-up period of 4 weeks.

03

Conditions studied

  • Pulmonary Tuberculosis

Keywords

  • Tuberculosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged between 18 and 65 years.
  2. Body weight between 40 and 90 kg.
  3. Newly-treated drug sensitivity tuberculosis: clinically diagnosed as pulmonary tuberculosis, without treatment, sputum smear-positive for acid-fast bacilli (AFB at least 1+), and no resistant to rifampicin or isoniazid in the drug sensitivity test.
  4. Drug-resistant tuberculosis: re-treatment pulmonary tuberculosis patients, diagnosed as rifampicin resistance (RR-TB) or isoniazid and rifampicin resistance (MDR-TB) by molecular biology methods, and sputum smear-positive for acid-fast bacilli. Patients must be willing to discontinue all TB drugs to allow 7 days washout.
  5. Patients must consent to -testing, or provide HIV-negative report within 6 months.
  6. Women are not breastfeeding or pregnant, and agree to practice effective throughout the trial.
  7. Provide voluntary and written prior to all trial-related procedures, agree to comply with the requirements and restrictions listed in the informed consent form and agreement.

Exclusion criteria

Exclusion Criteria:

  1. Patients with infection.
  2. Patients with miliary tuberculosis or extrapulmonary tuberculosis judged by the investigator.
  3. Patients with certain /QTc interval characteristics as described in the protocol.
  4. the patients have a history of, or current evidence of unstable or severe cardiovascular, kidney, liver, blood, tumor, endocrine and metabolic, mental or rheumatic diseases, or any other condition that will not be suitable to participate in this study, according to the judgement of the investigator.
  5. Patients who have participated in other clinical studies within 8 weeks prior to trial start.
  6. Patients having a known or suspected or serious adverse reaction to drugs used in this trial.
  7. Women who are pregnant, breastfeeding, or planning to become pregnant.
  8. Current or past history of alcohol and/or drug use that, in the investigator's opinion, would compromise the participant's safety or compliance to the study protocol procedures.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Arm A: WX-081

    Participants with newly-treated drug sensitivity tuberculosis receive WX-081 150mg orally once daily for 2 weeks.

    Drug: WX-081

  • Experimental
    Arm B: WX-081

    Participants with newly-treated drug sensitivity tuberculosis receive WX-081 300mg orally once daily for 2 weeks.

    Drug: WX-081

  • Experimental
    Arm C: WX-081

    Participants with newly-treated drug sensitivity tuberculosis receive WX-081 450mg orally once daily for 2 weeks.

    Drug: WX-081

  • Active comparator
    Arm D: Standard treatment

    Participants with newly-treated drug sensitivity tuberculosis receive standard treatment for two weeks.

    Drug: Standard treatment

  • Experimental
    Arm E: WX-081+MBT

    Participants with drug-resistant tuberculosis receive WX-081 400mg orally once daily for 2 weeks, and then MBT+ WX-081 150mg orally once daily for 6 weeks.

    Drug: WX-081 · Drug: Multi-drug background treatment (MBT)

  • Active comparator
    Arm F: Bedaquiline+MBT

    Participants with drug-resistant tuberculosis receive Bedaquiline 400mg orally once daily for 2 weeks, and then MBT+ Bedaquiline 200mg orally 3 times per week for 6 weeks.

    Drug: Bedaquiline · Drug: Multi-drug background treatment (MBT)

Interventions

  • DrugWX-081

    WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.

  • This licensed drug will be used in arm F as positive comparator.

  • DrugStandard treatment

    Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.

  • DrugMulti-drug background treatment (MBT)

    MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.

06

What researchers measure

Primary outcomes

  1. Time to positive (TTP)

    TTP is measured as time to sputum culture positivity in Liquid Culture Media.

    Time frame: Day 0-14.

  2. Early bactericidal activity (EBA) of WX-081

    EBA is measured as the mean rate of colony forming unit (log10CFU) of mycobacterium tuberculosis per ml sputum on solid medium in different time periods.

    Time frame: Day 0-14.

Secondary outcomes

  1. change of electrocardiogram QT interval

    QT interval is calculated as QTcF in milliseconds (ms)

    Time frame: Measured through 8 Weeks.

  2. The percentage of participants with sputum culture-negative conversion.

    Percentage of participants with an occurrence of sputum culture-negative through 8 weeks.

    Time frame: Measured through 8 Weeks.

  3. Rate of change of colony forming units (CFU)

    Rate of change of colony forming units (CFU) of mycobacterium tuberculosis on sputum culture through 8 weeks.

    Time frame: Measured through 8 Weeks.

  4. The percentage of participants with sputum smear-negative conversion.

    Percentage of participants with an occurrence of sputum smear-negative through 8 weeks.

    Time frame: Measured through 8 Weeks.

  5. heart rate

    heart rate in times per minute.

    Time frame: Measured through 8 Weeks.

  6. blood pressure

    blood pressure in mmHg

    Time frame: Measured through 8 Weeks.

  7. Maximum plasma concentration (Cmax)

    Blood samples will be taken at different time points before and after administration on Day1 and Day14 of treatment.

    Time frame: At day1 and 14.

  8. Time to reach maximum plasma concentration (Tmax)

    Blood samples will be taken at different time points before and after administration on Day1 and Day14 of treatment.

    Time frame: At day1 and 14.

  9. Area under the plasma concentration versus time curve (AUC(0-t))

    Blood samples will be taken at different time points before and after administration on Day1 and Day14 of treatment.

    Time frame: At day1 and 14.

  10. Terminal plasma half-life (t1/2)

    Blood samples will be taken at different time points before and after administration on Day1 and Day14 of treatment.

    Time frame: At day1 and 14.

07

Study locations

1 site
  • Beijing Chest Hospital affiliated to Capital Medical University
    Beijing, Beijing 101149, China
08

References and documents

Publications

  • Huang Z, Luo W, Xu D, Guo F, Yang M, Zhu Y, Shen L, Chen S, Tang D, Li L, Li Y, Wang B, Franzblau SG, Ding CZ. Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent. Bioorg Med Chem Lett. 2022 Sep 1;71:128824. doi: 10.1016/j.bmcl.2022.128824. Epub 2022 May 27. PubMed 35636648 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Apr 2022, 17 months.

Of 43 phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2020
First posted
Oct 30, 2020
StartActual
Oct 16, 2020
Primary completionActual
Apr 13, 2022
CompletionActual
Apr 13, 2022
Last update
Sep 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04608955
Lead sponsor
Shanghai Jiatan Pharmatech Co., Ltd
Responsible party
Sponsor
First posted
Oct 30, 2020
Start date
Oct 16, 2020
Primary completion
Apr 13, 2022
Completion
Apr 13, 2022
Last update
Sep 11, 2023

Study contacts

Song AiYun, MD
study chair · Shang hai Jiatan Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sudapyridine

Start the discussion